Abstract
Objective: To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment.
Methods: Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS) tablets for 8 weeks. Global similarity degree analysis and nonlinear mixed effects modeling (NONMEM) were employed to reveal the cutoff points and influencing factors in dynamic changes in the SAP phenotypic group. The phenotypic group was defined as the six phenotypes in SAP, including angina, choking sensation in the chest, palpitations, dark purple lips, ecchymosis on the tongue, and fine-choppy pulse, which were quantitatively evaluated on Days 0, 14, 28, 42, and 56.
Results: Variation in the six individual phenotypes and distribution of the SAP phenotypic profile were similar between the two experimental groups, but cutoff points for changes in the SAP phenotypic group were 7.28 and 10.73 weeks in XXK and CDS groups, respectively. Degree of severity of SAP as well as study site significantly affected the tendency for change in the SAP Xueyu Zheng in both XXK and CDS treatment groups. Different Chinese patent drugs affected the tendency for change in phenotypic group in patients with SAP. XXK was superior to CDS in controlling a clinical phenotypic group.
Conclusion: Based on global similarity degree analysis and NONMEM, the cutoff point and influencing factors in phenomic variation of SAP may be determined, to improve the development and modification of treatment regimens.
Keywords: Stable angina pectoris, similarity degree analysis, nonlinear mixed effect model, treatment effectiveness.
Current Vascular Pharmacology
Title:Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial
Volume: 13 Issue: 4
Author(s): Guo-Xin Li, Yong-Yan Wang, Chun-Ti Shen, Zhong Wang, Lei Zhang, Qi-guang Chen, Song-Shan Liu, Shu-Rong Liu, Zhuo-Ming Li, Xiao-Feng Wang, Jie Xue, Dong-Hai Wang, Bo Dong, Li-Ying Wang, Xi-Yan Yang, Xiang-Ling Liu, Si-Yuan Hu, Zhi-Wei Jing, Li-Ya Su, Hong-Li Wu, Bi-Wei Chen, Ya-Nan Yu, Wei Lu, Jun Liu and Jian-Yuan Tang
Affiliation:
Keywords: Stable angina pectoris, similarity degree analysis, nonlinear mixed effect model, treatment effectiveness.
Abstract: Objective: To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment.
Methods: Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS) tablets for 8 weeks. Global similarity degree analysis and nonlinear mixed effects modeling (NONMEM) were employed to reveal the cutoff points and influencing factors in dynamic changes in the SAP phenotypic group. The phenotypic group was defined as the six phenotypes in SAP, including angina, choking sensation in the chest, palpitations, dark purple lips, ecchymosis on the tongue, and fine-choppy pulse, which were quantitatively evaluated on Days 0, 14, 28, 42, and 56.
Results: Variation in the six individual phenotypes and distribution of the SAP phenotypic profile were similar between the two experimental groups, but cutoff points for changes in the SAP phenotypic group were 7.28 and 10.73 weeks in XXK and CDS groups, respectively. Degree of severity of SAP as well as study site significantly affected the tendency for change in the SAP Xueyu Zheng in both XXK and CDS treatment groups. Different Chinese patent drugs affected the tendency for change in phenotypic group in patients with SAP. XXK was superior to CDS in controlling a clinical phenotypic group.
Conclusion: Based on global similarity degree analysis and NONMEM, the cutoff point and influencing factors in phenomic variation of SAP may be determined, to improve the development and modification of treatment regimens.
Export Options
About this article
Cite this article as:
Li Guo-Xin, Wang Yong-Yan, Shen Chun-Ti, Wang Zhong, Zhang Lei, Chen Qi-guang, Liu Song-Shan, Liu Shu-Rong, Li Zhuo-Ming, Wang Xiao-Feng, Xue Jie, Wang Dong-Hai, Dong Bo, Wang Li-Ying, Yang Xi-Yan, Liu Xiang-Ling, Hu Si-Yuan, Jing Zhi-Wei, Su Li-Ya, Wu Hong-Li, Chen Bi-Wei, Yu Ya-Nan, Lu Wei, Liu Jun and Tang Jian-Yuan, Dynamic Changes in Phenotypic Groups in Patients with Stable Angina Pectoris after Treatment with Xinxuekang Capsule: A Randomized Controlled Trial, Current Vascular Pharmacology 2015; 13 (4) . https://dx.doi.org/10.2174/1570161112666141014151858
DOI https://dx.doi.org/10.2174/1570161112666141014151858 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Total Lipids and Fatty Acid Methyl Esters of Germinated Seeds of Mangrove Wild Legume
Current Nutrition & Food Science Regulation of Inflammation: A Review of Recent Advances in Anti- Inflammatory Strategies
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Statins for Diabetic Cardiovascular Complications
Current Vascular Pharmacology The Role of microRNA-126 in Vascular Homeostasis
Current Vascular Pharmacology Physiologic Tailoring of Treatment in Resistant Hypertension
Current Cardiology Reviews Resveratrol and Stroke: from Chemistry to Medicine
Current Neurovascular Research A Therapeutic Target of Cerebral Hemorrhagic Stroke: Matrix Metalloproteinase- 9
Current Drug Targets Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Emerging Role for RBM20 and its Splicing Substrates in Cardiac Function and Heart Failure
Current Pharmaceutical Design Novel Biomarkers Assessing Endothelial Dysfunction: Role of microRNAs
Current Topics in Medicinal Chemistry Vitamin D Deficiency May Be Associated with a More Rapid Decline in CD4 Cell Count to <350 Cells/µL in Untreated HIV-Infected Adults
Current HIV Research Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology Cardiovascular-Related
Current Bioactive Compounds Visfatin/PBEF and Atherosclerosis-Related Diseases
Current Vascular Pharmacology Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism Clinical Approach to Diabetic Cardiomyopathy: A Review of Human Studies
Current Medicinal Chemistry Patent Selections
Recent Patents on Biotechnology Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms
Cardiovascular & Hematological Disorders-Drug Targets